Open access
Open access
Powered by Google Translator Translator

Cardiomyopathies

Retrospective Cohort Study | Natural history of MYH7-related dilated cardiomyopathy.

14 Sep, 2022 | 13:06h | UTC

Natural History of MYH7-related Dilated Cardiomyopathy – Journal of the American College of Cardiology

 


20-year follow-up of a RCT trial | Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy.

26 Jul, 2022 | 13:33h | UTC

Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial – European Heart Journal

Commentary: Immunosuppression may benefit long term in virus-negative inflammatory cardiomyopathy – Healio (free registration required)

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by/4.0/ license

 


RCT | Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

13 Jul, 2022 | 11:52h | UTC

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy – Journal of the American College of Cardiology

Related: #ACC22 [Not published yet] – RCT: Mavacamten reduces the need for surgical intervention in patients with obstructive hypertrophic cardiomyopathy.

 


RCT | First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation.

11 Jul, 2022 | 12:21h | UTC

First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial – Circulation

 

Commentary on Twitter

 


Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.

8 Jul, 2022 | 11:53h | UTC

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia – Clinical Cardiology

Related:

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis – European Heart Journal

Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021 – Arquivos Brasileiros de Cardiologia

AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases – European Heart Journal

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association – Circulation

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis – Canadian Journal of Cardiology

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management – JACC: CardioOncology

Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis – Circulation: Heart Failure

 


Case Series | Myocardial injury in patients with acute and subacute Chagas Disease in the Brazilian Amazon using cardiovascular magnetic resonance.

5 Jul, 2022 | 11:47h | UTC

Myocardial Injury in Patients With Acute and Subacute Chagas Disease in the Brazilian Amazon Using Cardiovascular Magnetic Resonance – Journal of the American Heart Association


Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator.

5 Jul, 2022 | 11:29h | UTC

Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator – European Heart Journal

Related Study: Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator – European Heart Journal

Editorial: Arrhythmogenic right ventricular cardiomyopathy: the never-ending quest for a risk calculator


Cohort Study | Novel risk prediction model to determine adverse heart failure outcomes in arrhythmogenic right ventricular cardiomyopathy.

4 Jul, 2022 | 11:53h | UTC

Novel Risk Prediction Model to Determine Adverse Heart Failure Outcomes in Arrhythmogenic Right Ventricular Cardiomyopathy – Journal of the American Heart Association

Editorial: Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy


Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside.

29 Jun, 2022 | 11:01h | UTC

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside – Drugs

 


Brief Review | Never above suspicion: getting to the bottom of cardiac sarcoidosis diagnosis and treatment.

29 Jun, 2022 | 10:50h | UTC

Never Above Suspicion: Getting to the Bottom of Cardiac Sarcoidosis Diagnosis and Treatment – American College of Cardiology

 


Indications and utility of cardiac genetic testing in athletes.

28 Jun, 2022 | 11:03h | UTC

Indications and utility of cardiac genetic testing in athletes – European Journal of Preventive Cardiology

 


Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada.

27 Jun, 2022 | 11:51h | UTC

Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada – JAMA Network Open

Commentary: Young Men’s Myocarditis Risk 5 Times Higher With Moderna vs Pfizer Vax — But Canadian study finds that 8-week interval before second dose attenuates some of the risk – MedPage Today (free registration required)

 


Cohort Study: Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA.

22 Jun, 2022 | 12:07h | UTC

Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases – The Lancet

Commentaries:

COVID-19 mRNA vaccination and myocarditis or pericarditis – The Lancet

Myocarditis and Pericarditis After the COVID-19 mRNA Vaccination – American College of Cardiology

Related:

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents – JAMA Cardiology

Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals – UK Health Security Agency

Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 


Stay Updated in Your Specialty

No spam, just news.